Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4088044 · 1 trial · 1 indication
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4088044 (Part A) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4088044 administered intravenously (IV) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Administered IV |
| LY4088044 (Part B) | EXPERIMENTAL | SAD of LY4088044 administered subcutaneously (SC) |
| Placebo (Part B) | PLACEBO_COMPARATOR | Administered SC |
| LY4088044 (Part C) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4088044 administered IV |
| Placebo (Part C) | PLACEBO_COMPARATOR | Administered IV |
| Name | Type | Description |
|---|---|---|
| LY4088044 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring * Have a body mass index (BMI) within the range 18.5 to 30 kilogram per square meter (kg/m²) Exclusion Criteria: * A...
LY4088044 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single trial enrolling healthy adult volunteers. No therapeutic indication has been disclosed for the compound.
LY4088044 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants.
LY4088044 is in Phase 1 clinical development. It has not been approved by the FDA and remains investigational. One Phase 1 trial is currently recruiting, and no trials have been completed.
LY4088044 is being studied in one Phase 1 trial, NCT07090785, titled A Study of LY4088044 in Healthy Participants. The trial is recruiting 104 healthy volunteers across the United States, New Zealand, and Singapore, and it is randomized, double-blind, and placebo-controlled.
The Phase 1 trial of LY4088044, NCT07090785, is a randomized, double-blind, placebo-controlled study in healthy participants. It plans to enroll 104 adults aged 18 years and older of all sexes. Participants are being recruited in the United States, New Zealand, and Singapore.